Journal of Clinical Microbiology, November 1999, p. 3469-3474, Vol. 37, No. 11
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Invasive and Noninvasive Group A Streptococcal
Isolates with Different speA Alleles in The Netherlands:
Genetic Relatedness and Production of Pyrogenic Exotoxins A and
B
Ellen M.
Mascini,1,*
Margriet
Jansze,1
Leo M.
Schouls,2
Ad C.
Fluit,1
Jan
Verhoef,1 and
Hans
van Dijk1
Eijkman-Winkler Institute for Microbiology,
Infectious Diseases, and Inflammation, Utrecht University Hospital,
Utrecht,1 and The National Institute for
Public Health and the Environment (RIVM),
Bilthoven,2 The Netherlands
Received 16 April 1999/Returned for modification 21 June
1999/Accepted 22 July 1999
 |
ABSTRACT |
Streptococcal pyrogenic exotoxin A (SPE-A) and SPE-B have been
implicated in the pathogenesis of severe group A streptococcal (GAS)
disease. We studied 31 invasive GAS strains including 18 isolates from
patients with toxic shock syndrome and 22 noninvasive strains isolated
in The Netherlands between 1994 and 1998. These strains were associated
with the different allelic variants of the gene encoding SPE-A. We
selected endemic strains with speA-positive M and T
serotypes: speA2-associated M1T1 and M22-60T12 strains, speA3-associated M3T3 strains, and
speA4-associated M6T6 strains. Since
speA1-positive isolates were not frequently encountered, we
included speA1 strains of different serotypes. The GAS
strains were compared genotypically by pulsed-field gel electrophoresis and phenotypically by the in vitro production of SPE-A and SPE-B. All
strains within one M and T type appeared to be of clonal origin. Most
strains produced SPE-A and SPE-B, but only a minority of the
speA4-positive isolates did so. Among our isolates,
speA1- and speA3-positive strains produced
significantly more SPE-A than speA2- and
speA4-carrying strains, while SPE-B production was most
pronounced among speA1- and speA2-containing
strains. There was a marked degree of variability in the amounts of
exotoxins produced in vitro by strains that shared the same genetic
profile. We conclude that the differences in the in vitro production of SPE-A and SPE-B between our selected strains with identical M and T
types were not related to either genetic heterogeneity or the clinical
course of GAS disease in the patient from whom they were isolated.
 |
INTRODUCTION |
Although group A streptococcal (GAS)
isolates are generally considered noninvasive pathogens that cause
localized infections of nasopharyngeal mucosal surfaces and the skin,
increasing numbers of reports have described invasive infections
worldwide that result in necrotizing fasciitis, a toxic shock-like
syndrome (TSS), and death (7, 15, 29, 38, 40, 44). Despite
significant study, the cause of episodic changes in the severity of GAS
disease has not yet been elucidated. Several factors have been
implicated in the pathogenesis of severe GAS infections, including a
decrease in herd immunity and the introduction of highly virulent
mutant strains. The emergence of certain strain types, like M1T1 and M3T3, among invasive GAS isolates symbolizes the epidemiology of GAS
pathogenicity (10, 14, 15, 29, 40, 41, 45). After a long
period of absence, these strains, which are associated with
streptococcal pyrogenic exotoxin A (SPE-A), started reappearing in
several countries. SPEs belong to the major virulence factors in the
pathogenesis of severe GAS infections. They show a remarkable degree of
homology with staphylococcal enterotoxins B and C and are considered
superantigens, exerting a series of important biological effects on the
host, including the massive release of cytokines and the consequent
induction of fever, erythematous skin reactions, and polyclonal T-cell
activation (1, 3, 5, 6, 24, 39).
Different streptococcal exotoxins are known, and these have been
designated SPE-A, SPE-B, SPE-C, SPE-F, and streptococcal superantigen
(17, 27, 35, 44, 45). The highly conservative chromosomal
gene encoding SPE-B (speB) is present in practically 100%
of the GAS strains (4). It has been documented that SPE-B is
identical to or is an allelic variant of streptococcal proteinase precursor (12, 13); it cleaves the interleukin 1
precursor and extracellular matrix proteins such as fibronectin
(17, 18). Moreover, SPE-B appears to be involved in tissue
invasion and destruction (22, 23). In addition, several
reports have suggested an important role for SPE-B in the pathogenesis
of serious GAS disease (15, 22, 23, 34). SPE-A and SPE-C are
phage encoded, and their presence is restricted to a limited number of
strains (29, 46). Far more streptococcal isolates from
patients with TSS, other invasive GAS disease, or scarlet fever have
been reported to produce SPE-A or at least to possess the gene that
encodes SPE-A (speA) than GAS isolates in general (14,
20, 21, 29, 40, 43, 44). Four naturally occurring isotypes of
SPE-A have been described: SPE-A1, SPE-A2, SPE-A3, and SPE-A4. The
newer variants, SPE-A2 and SPE-A3, differ from the ancient SPE-A1 by one amino acid, whereas the most recently described isotype, SPE-A4, shows only 91% homology with the other allelic variants
(32).
In this investigation, we studied speA-positive GAS isolates
with certain M types which were isolated frequently in The Netherlands from 1994 to 1998 for the estimation of SPE-A and SPE-B production in
vitro by comparing isolates that carry different speA
alleles. For this purpose, we developed a sensitive technique for the
detection of SPE-A and SPE-B produced by GAS isolates. Using this
assay, we collected quantitative information on the production of SPE-A and SPE-B and related our data to the presence of speA1,
speA2, speA3, or speA4 alleles in
speA-positive GAS strains. In this study, we made a
distinction between invasive isolates from patients with and without
TSS and noninvasive throat isolates. Genetic heterogeneity among
strains of the same M type was determined by pulsed-field gel
electrophoresis (PFGE).
 |
MATERIALS AND METHODS |
Microorganisms.
A total of 53 clinical GAS strains were
collected from Dutch patients during the period from 1994 to 1998 within the framework of a nationwide GAS surveillance program.
Thirty-one invasive GAS strains were recovered from normally sterile
sites. Twenty-two noninvasive strains were obtained from pharyngitis
patients, who showed no signs of invasive infection. All GAS strains
originated from different patients and were stored at
70°C upon
receipt. Laboratory strains NY-5 (SPE-A positive), 279 (SPE-A negative but SPE-B positive), and A95/216 (SPE-B negative) were used as assay controls.
Strain typing.
For the characterization of isolates, T
serotyping and M genotyping were performed as described by Kaufhold et
al. (19). In addition, PCR technology was used to detect the
speA, speB, and speC genes.
Biotin-labeled oligonucleotide probes specific for speA1
(AACGTTGATATTTATGGT), speA2
(GATAAAAACATTGATATT), speA3 (GATATTTATAGTGTAGAA), and speA4
(GAAGAGCGTGTATTTATGGAGGGG) were used in a Southern blot
hybridization of the PCR products to differentiate between the exotoxin
variants as described by Schouls (42). Invasive and
superficial GAS strains positive for speA1,
speA2, speA3, or speA4 were selected,
subjected to molecular typing, and tested for their production of SPE-A
and SPE-B.
PFGE.
PFGE was performed with the Genepath group 1 reagent
kit (Bio-Rad, Hercules, Calif.) as described in the instruction manual. Briefly, in situ cell lysis was carried out by overnight incubation at
37°C in Lysis Buffer I and lysozyme-lysostaphin. Proteolysis was
achieved by overnight incubation at 50°C with proteinase K in
proteinase K buffer. Then, the plugs were washed thoroughly and stored
at 4°C. Next, DNA inserts were digested overnight at room temperature
with 25 U of the SmaI enzyme in SmaI buffer per plug, followed by separation of the fragments at 180 V with a CHEF-DR
II apparatus (Bio-Rad) with pulse times ranging from 5 to 50 s
over 24 h. Polymerized bacteriophage lambda DNA standards (Bio-Rad) were used as molecular size markers. Gels were stained with
ethidium bromide and were photographed under UV light, after which the
PFGE patterns were compared visually. Restriction analysis of strains
belonging to the same M type was performed simultaneously in the same run.
Culture and production of SPE-A and SPE-B.
Aliquots of
freshly thawed bacteria were grown on fresh blood agar plates and were
subsequently cultured in Todd-Hewitt broth (Difco, Detroit, Mich.)
supplemented with 0.3% (wt/vol) glucose, 0.2% (wt/vol)
NaHCO3, 0.2% (wt/vol) NaCl, 0.08% (wt/vol)
Na2HPO4, and 0.02% (wt/vol)
L-glutamine. The strains were sequentially grown twice at
37°C for 3 h to reach the logarithmic phase, followed by
overnight culture to attain the stationary phase. The bacteria were
spun down, and supernatants from the final culture were concentrated six times by ethanol precipitation. Subsequently, exotoxin-enriched preparations were subjected to inhibition enzyme-linked immunosorbent assay (ELISA) for the estimation of SPE-A and SPE-B production.
Antigens.
SPE-A was isolated from GAS strain NY-5 as
described previously (26). SPE-B was kindly provided by
J. M. Musser (Baylor College of Medicine, Houston, Tex.).
Both antigens were
99% pure, as determined by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis combined with silver
staining (26).
Antibodies against SPE-A and SPE-B.
High-titer serum from a
selected healthy individual was used as the source of polyclonal
antibodies against SPE-A and SPE-B.
Detection of SPE-A and SPE-B produced by GAS strains.
SPE
production by the GAS strains to be tested was determined by
competitive ELISAs. Ninety-six-well flat-bottom microtiter ELISA plates
(3590; Costar, Cambridge, Mass.) were coated for 1 h with 100 µl
of SPE-A or SPE-B (0.5 µg/ml in saline). Unless otherwise mentioned,
all incubation steps were performed at 37°C. Phosphate-buffered
saline supplemented with 0.1% Tween 20 was used in the washing
procedures. Blocking was performed with 150 µl of 0.1% gelatin in
twice-distilled water. Concentrated supernatants were then serially
diluted in 96-well, flat-bottom microtiter plates (Greiner GmbH,
Frickenhausen, Germany), mixed 1:1 with our high-titer reference serum
(final concentration, 1:2,000), and incubated at 37°C for 1 h
until equilibrium was reached. Aliquots of 100 µl were pipetted into
the coated plates, and the plates were incubated for 1 h. Next,
the plates were incubated with peroxidase-labeled sheep anti-human
immunoglobulin G (IgG), and the ELISAs were developed with a hydrogen
peroxide-3,3',5,5'-tetramethylbenzidine mixture as the substrate. The
optical densities (ODs) in the wells were determined with an ELISA
microplate reader (Bio-Rad) operated at 450 nm. The OD values measured
in the absence of the supernatant were taken as 100% reference values.
Supernatants from strains NY-5 and 279 were used as SPE-A-positive and
SPE-A-negative controls, respectively, while supernatants from strains
279 and 95/126 were used as SPE-B-positive and SPE-B-negative controls,
respectively. All experiments were performed in triplicate. The
inhibition of ELISA reactivity was used as a measure for SPE-A or
SPE-B. Supernatant preparations from the strains which were included in
this study were tested at five dilutions in washing buffer: as such and
at 1:3, 1:10, 1:30, and 1:100. We used a 30% reduction of the positive control OD at 450 nm (OD450) as the threshold for exotoxin
production. The highest dilution of concentrated supernatant which
induced significant inhibition was used for the quantitation of toxin production. SPE production was depicted in arbitrary units, which represent the reciprocal value of the highest dilution of supernatant that induced
30% inhibition of ELISA reactivity. In our procedures, the lower detection limits for SPE-A and SPE-B were 5 and 1 ng/ml, respectively.
Statistics.
The nonparametric Kruskal-Wallis test was used
to compare the production of SPE-A or SPE-B by GAS strains of different
M/T types. Differences with P values below 0.05 were
considered significant.
 |
RESULTS |
Typing of bacterial isolates.
After M and T typing and the
determination of spe profiles, 53 clinical GAS isolates, of
which 22 were noninvasive and 31 were invasive (18 isolates from
patients with TSS and 13 isolates from patients with less severe
infections), were included in the study. All isolates harbored
speA and speB genes. The bacterial isolates
comprised 17 M1T1 strains, 17 M3T3 strains, 5 M6T6 strains, and 9 M22-60T12 strains. Strains that possessed the speA1 allele were sporadically identified among both invasive and noninvasive isolates and were not found in association with any particular M or T
strain type; five speA1-positive isolates of different types
were included. The speA alleles and the clinical sources of
the isolates are shown in Table 1.
A 100% correlation was observed between the following combinations:
M1T1 strains and the speA2 gene, M22-60T12 strains and the
speA2 gene, M3T3 strains and the speA3 gene, and
M6T6 strains and the speA4 gene. All M and T types included
were recovered from both invasive and noninvasive sites; M22-60T12
strains were predominantly isolated from pharyngeal swabs and were only
sporadically isolated from normally sterile body compartments.
PFGE.
All isolates were subjected to PFGE, and most banding
patterns between isolates that carried the same M protein were
indistinguishable when restriction was done with SmaI (Fig.
1). For none of the strains were more
than two fragment differences observed between strains of similar M and
T types. Thus, all of the strains of a particular M and T type were
considered to be of similar clonal origin. No major differences in PFGE
patterns were observed between isolates of identical M and T types
recovered from patients with TSS, otherwise invasive GAS isolates, or
isolates from patients with pharyngitis. The five
speA1-positive isolates each belonged to different
serotypes, and all had different PFGE profiles (data not shown).

View larger version (100K):
[in this window]
[in a new window]
|
FIG. 1.
PFGE banding patterns of GAS strains specific for
different M serotypes. Lanes: M, marker; M1, M1T1; M3, M3T3; M6, M6T6;
M22-60, M22-60T12.
|
|
Production of SPE-A and SPE-B.
The production of SPE-A and
SPE-B by these GAS strains was quantitated by competitive ELISA.
Exotoxin-enriched supernatants were first incubated in solution with
high-titer human serum at fixed concentrations as a source of
anti-SPE-A and anti-SPE-B antibodies until equilibrium was reached. The
concentration of free antibodies was then determined by ELISA. In order
to guarantee the specificity of the assay, inhibition of ELISA
reactivity was determined with supernatant preparations for negative
control strains (strain 279 for SPE-A production and strain A95/126 for SPE-B production). OD values for the plates coated with SPE-A or SPE-B
were identical to the values observed for the plates with Todd-Hewitt
broth growth medium, indicating that cross-reactivity between the
coating and other GAS products excreted into the supernatant did not
occur. The supernatant preparation for strain NY-5, our source for the
purification of SPE-A, was used as a positive control for the
production of SPE-A (Fig. 2).

View larger version (9K):
[in this window]
[in a new window]
|
FIG. 2.
Principles of competitive ELISA for SPE-A. (A) The serum
concentration appropriate for the competitive ELISA was deduced from
the linear part of the dose-response curve obtained in the ELISA for
SPE-A. (B) Supernatant preparations of the strains were incubated at
several concentrations to equilibrium with a fixed serum concentration
as determined from panel A. SPE-A-coated ELISA plates were incubated
with this equilibrated mixture, and unbound antibody levels were
subsequently determined. A 30% inhibition of the OD450 was
taken as the lower threshold to designate a exotoxin-producing
strain.
|
|
Similarly, the supernatant preparation for strain 279 was tested as a
positive control for the production of SPE-B. The production of SPE-A
and SPE-B by individual GAS strains is presented in Fig. 3. The majority of isolates were found to
produce SPE-A as well as SPE-B in vitro. Significant differences in the
amounts of SPE-A and SPE-B produced were observed between groups of
strains with different speA allelic variants (P < 0.0005). Of the clinical isolates tested, SPE-A was detected in
supernatant preparations for all speA1-, speA2-,
and speA3-positive strains. speA4-positive strains did not always cause inhibition. The speA1- and
speA3-positive strain types did not produce significantly
different concentrations of SPE-A. Furthermore, no significant
differences in SPE-A production were demonstrated between M22-60T12 and
M6T6 strains. speA1 and speA3 strains produced
significantly larger amounts of SPE-A than speA2 and
speA4 strains (P < 0.005). The level of
SPE-A production by M1T1 strains was lower than that by
speA1 strains and speA3 M3T3 strains
(P < 0.001) but was higher than that by M22-60T12 and
M6T6 strains (P = 0.04).

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 3.
Production of SPE-A (A) and SPE-B (B) by clinical GAS
isolates as determined by competitive ELISA. SPE production is depicted
in arbitrary units (AU), which represent the reciprocal value of the
lowest dilution of supernatant which induced 30% inhibition of ELISA
reactivity. Invasive isolates are represented by closed dots;
noninvasive isolates are represented by open dots.
|
|
Overall, SPE-B was detected at higher concentrations than SPE-A. No
significant differences in the levels of SPE-B were observed between
speA1 and speA2 strains. In addition, no
significant differences in the levels of SPE-B were found between
speA3 and speA4 isolates. The level of production
of SPE-B by speA1 isolates and speA2-positive strains of the M1T1 or M22-60T12 serotypes was significantly higher than that by M3T3 and M6T6 strains, some of which did not synthesize measurable amounts of SPE-B (P < 0.0005). The levels
of exotoxin production in broth medium by strains of identical M types
varied widely from none to strong, but no significant differences in SPE production by strains from patients with TSS, otherwise invasive strains, or noninvasive strains were observed.
 |
DISCUSSION |
In this study, we investigated the production of SPE-A and SPE-B
by 53 endemic GAS strains and compared the levels of production by
strains carrying different speA allelic variants. For this purpose, we included serotypes M1T1, M22-60T12, M3T3, and M6T6, which
were recovered from patients with severe or mild GAS disease in The
Netherlands during the period from 1994 to 1998 and which corresponded
to the different speA allelic variants. Consequently, the
isolates that were analyzed did not represent the wide variety of GAS
types present in the community. In accordance with other Dutch M1T1,
M3T3, and M6T6 types, all our strains hybridized with a probe specific
for speA (40). M1T1 and M3T3 types accounted for
about 50% of the Dutch isolates from patients with TSS, but the same
types were also, now and then, encountered as causes of noninvasive
infections (40, 41). Conspicuously, M22-60T12 isolates were
often recognized among strains from patients with pharyngitis. Since
the speA4 allele was detected only in M6T6 isolates, M6T6
types were included in the present study as well. Since
speA1-positive strains only rarely occurred, we included five speA1-positive isolates which were of different M and T
types for the detection of the production of exotoxins A1 and B. All M1T1 and M22-60T12 types contained speA2, all M3T3 types
contained speA3, and all M6T6 types contained
speA4. These data are in line with those from Swedish and
Finnish studies that showed that all M1 strains possess the
speA gene (15, 28, 33). In striking contrast, the
connection between M1 and M3 strains and the speA gene among
U.S. isolates was considerably lower (8). These large
discrepancies with regard to the occurrence of speA may be
related to the geographic region of where the strain is isolated.
PFGE was performed to discover whether toxin expression could be
related to the genetic differences within strains of similar M and T
types. The value of PFGE with SmaI in the molecular
epidemiological typing of Streptococcus pyogenes, has been
well established, yielding suitable and discriminatory macrorestriction
patterns (2, 43, 47). Among the restricted numbers of
isolates in our study, we could not detect significant differences in
banding patterns between strains that shared identical M and T types.
Moreover, regardless of the sources of the clinical isolates, all GAS
isolates with similar M and T types appeared to be derived from the
same genetic lineage, even though they may have originated from
different regions of the country. These results are in line with those
of others who did not find a correlation between the genomic type and
the severity or outcome of disease among M1T1 isolates (28, 33). Accordingly, several other previous reports have
demonstrated a strong clonality of M1T1 strains from different parts of
the world (10, 25, 29-31, 43). While substantial genetic
diversity among M1-expressing organisms has, however, been described, a single subclone that carries the speA gene and that has been
recovered worldwide, including The Netherlands, was involved in most
invasive episodes (25, 28, 31, 33). It seems obvious that
our M1 isolates belong to this globally spread clone, which has been designated restriction fragment length polymorphism type 1a.
Furthermore, Upton et al. (47) recently identified two
subclones within the M3 type, and both of them contain the
speA gene.
Some investigators reported a direct correlation between logarithmic
growth and SPE-A production (16), while others mentioned that SPE-A is produced mainly during the short stationary interphases which interrupt growth (36). In contrast, SPE-B production
was detected only when cultures entered the stationary phase
(9). In our study, we tested exotoxin production in
bacterial supernatant preparations at several time points in 1- to 24-h
cultures starting from fresh mid-logarithmic-phase cultures. From these
experiments, exotoxin production appeared to be most pronounced with
two sequential incubations to the mid-logarithmic phase, followed by an
overnight culture. The results indicated that the majority of our
endemic strains containing the speA gene are indeed
producers of exotoxins A and B in vitro. Purified SPE-A from laboratory
strain NY-5 and human serum containing polyspecific IgG were used for
the estimation of SPE-A production; considerable inhibition of ELISA
reactivity was reached by all allelic SPE-A variants. Therefore, we
conclude that anti-SPE-A antibodies are cross-reactive with all four
allelic variants of SPE-A. As far as levels of SPE-A production were
concerned, speA1 and speA3 strains induced
significantly stronger inhibition than speA2 and
speA4 strains. We considered the possibility that the
anti-SPE-A antibodies in our reagent serum present a lower affinity or
neutralizing capacity toward SPE-A2, SPE-A3, and especially, SPE-A4
than toward SPE-A1; SPE-A1 differs from SPE-A2 and SPE-A3 by only one
amino acid, while the degree of homology with SPE-A4 is considerably
lower. These differences may have influenced the results, since our
ELISA plates were coated with NY-5-derived SPE-A1. However, subjection
of GAS supernatant preparations to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and silver staining yielded
results which were in line with the data obtained by inhibition ELISA
(data not shown).
Our high-titer serum also appeared to be appropriate for the
recognition of SPE-B. Our isolates generally produced SPE-B in larger
amounts than SPE-A. Strong exotoxin B production was common in
speA1 and speA2 strains, while nonproducers were
found among the speA3 and speA4 strains.
Interestingly, an enormous variation in the amounts of both SPE-A and
SPE-B produced by strains of identical M and T types was noticed. Since
these strains were indistinguishable by PFGE and were very likely
genetically related, we conclude that toxin production is regulated at
the transcription level. It is important to bear in mind that toxin
production in vitro may not accurately reflect the regulation of
protein expression in the host. In addition, it is not clear whether
SPE-A production by invasive strains occurs in response to
environmental conditions encountered in the host during tissue invasion
and/or whether the toxin contributes to the invasiveness of the strain.
The systemic effects in necrotizing fasciitis and TSS may be due to
synergistic effects involving multiple streptococcal products. It is
possible that speA is genetically linked to one or more
other genes involved in TSS. Recently, Cleary et al. (11)
reported that SPE-A expression is genetically unstable, suggesting the
existence of a common regulatory circuit linking intracellular
invasion, the M protein, the hyaluronic acid capsule, and SPE-A
expression and providing a reversible genetic switch mechanism by which
SPE-A and M1 expression could both vary (11).
Surprisingly, we observed higher percentages of SPE-A-producing strains
than several other investigators: Talkington et al. (45)
reported that 50% of M1 and M3 strains expressed SPE-A, Hauser et al.
(14) observed 100% SPE-A production by M3 strains versus
20% SPE-A production by M1 strains, and Chaussee et al. (8)
mentioned 43% SPE-A production by invasive speA-positive isolates. Holm and coworkers (15, 33) concluded that
Scandinavian M1 strains produce very little or no SPE-A but large
amounts of SPE-B, regardless of the clinical condition. We ascribe the
discrepancies between our results and those from other groups to
differences in procedures. Relative to other techniques that have been
used (14-16, 21), the inhibition ELISA that we used is a
very sensitive technique for the estimation of SPE-A and SPE-B, with
both exotoxins being detected in nanogram amounts. The high-titer human
serum that we used proved to be an excellent source of polyclonal
antibodies against SPE-A and SPE-B. Furthermore, hyaluronic acid, which
at high levels might interfere with the detection of SPE-A, did not disturb our assays, because the concentration factor of the bacterial supernatant preparations did not exceed sixfold.
Our data do not support the hypothesis that the clinical source of the
GAS isolate determines the in vitro production of either exotoxin. With
regard to this particular point, our data are in line with those of
others who suggest an absence of a correlation between SPE-B production
in vitro and the severity of GAS disease or any particular M type
(8, 15, 33, 37, 45). A strong association between SPE-A
production and the isolation of SPE-A-producing strains from patients
with TSS has, however, been observed (14, 21, 29, 45),
although the speA-positive TSS strains in those studies were
compared with speA-negative strains isolated from other
sources as well. Interestingly, a study with isolates with identical
restriction fragment length polymorphism patterns within families
showed that while the speA gene was maintained in all isolates, only invasive isolates expressed SPE-A in vitro
(8).
The increase in the incidence of invasive GAS disease is accompanied by
a shift in the appearance of speA alleles. Remarkably, the
speA1 allele was already observed in GAS strains isolated in
the first half of the century. Nowadays, however, speA1 is rarely found in current GAS strains, while speA2 and
speA3 are frequently encountered (30, 32). The
allelic variants of SPE-A may display qualitative or quantitative
heterogeneity in one or more of the functions ascribed to SPE-A. Thus,
it might be speculated that the allelic change from speA1
into speA2 or speA3 contributes to the
progressive virulence of the bacteria. Bradford Kline and Collins
(6) demonstrated that SPE-A3 has significantly enhanced mitogenic activity and affinity for class II MHC molecules those of
SPE-A1. In contrast, SPE-A2 has slightly higher affinity for class II
molecules than SPE-A1 but no increased mitogenic activity (6). Minor increases in production combined with the
enhanced activities of exotoxin A could, however, result in
disproportionate increases in toxicity and thus increased virulence in
the host. This might be the result of both higher-level toxin
production by SPE-A-positive strains compared with the for strains that
do not synthesize SPE-A and a reflection of the greater toxicity of the
current SPE-A alleles compared with that of the ancient SPE-A or other
streptococcal toxins (20, 21).
In conclusion, the majority of speA-positive GAS strains
endemic in The Netherlands synthesized SPE-A and SPE-B in vitro. In
general, the selected M and T serotypes in combination with the
speA allelic variants appeared to be correlated with the
expression of exotoxins, with SPE-A production being most pronounced in
our speA1 and speA3 strains and SPE-B production
being most significant in our speA1 and speA2
strains. Nevertheless, genetically related isolates of identical M and
T serotypes showed wide variations in levels of SPE-A and SPE-B
excretion in vitro, but these variations were not decisive for the
clinical course of disease: there were no significant differences in
the levels of in vitro production of SPE-A and SPE-B by strains from
patients with TSS, otherwise invasive strains, or noninvasive strains.
 |
ACKNOWLEDGMENTS |
We thank J. M. Musser for supplying SPE-B.
This work was supported by the Dutch Praeventie Fonds (project 002824180).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Eijkman-Winkler
Institute for Microbiology, Infectious Diseases, and Inflammation, Utrecht University Hospital G04.614, P.O. Box 85500, NL-3508 GA Utrecht, The Netherlands. Phone: 31-302 507627. Fax: 31-302 541770. E-mail: e.m.mascini{at}lab.azu.nl.
 |
REFERENCES |
| 1.
|
Abe, J.,
J. Forrester,
T. Nakahara,
J. A. Laferty,
B. L. Kotzin, and D. Y. M. Leung.
1991.
Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B.
J. Immunol.
146:3747-3750[Abstract].
|
| 2.
|
Bert, F.,
C. Branger, and N. Lambert-Zechovsky.
1997.
Pulsed-field gel electrophoresis is more discriminating than multilocus enzyme electrophoresis and random amplified polymorphic DNA analysis for typing pyogenic streptococci.
Curr. Microbiol.
34:226-229[Medline].
|
| 3.
|
Betley, M. J.,
D. W. Borst, and L. B. Regassa.
1992.
Staphylococcal enterotoxins, toxic shock syndrome toxin and streptococcal pyrogenic exotoxins: a comparative study of their molecular biology.
Chem. Immunol.
55:1-35[Medline].
|
| 4.
|
Black, C. M.,
D. F. Talkington,
T. O. Messmer,
R. R. Facklam,
E. Hornes, and O. Olsvik.
1993.
Detection of streptococcal pyrogenic exotoxin genes by a nested polymerase chain reaction.
Mol. Cell. Probes
7:255-259[Medline].
|
| 5.
|
Bohach, G. A.,
D. J. Fast,
R. D. Nelson, and P. M. Schlievert.
1990.
Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.
Crit. Rev. Microbiol.
17:251-272[Medline].
|
| 6.
|
Bradford Kline, J., and C. M. Collins.
1996.
Analysis of the superantigenic activity of mutant and allelic forms of streptococcal pyrogenic exotoxin A.
Infect. Immun.
64:861-869[Abstract].
|
| 7.
|
Carapetis, C.,
R. Robins-Browne,
D. Martin,
T. Shelby-James, and G. Hogg.
1995.
Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-nontypable clone.
Clin. Infect. Dis.
21:1220-1227[Medline].
|
| 8.
|
Chaussee, M. S.,
J. Liu,
D. L. Stevens, and J. J. Ferretti.
1996.
Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections.
J. Infect. Dis.
173:901-908[Medline].
|
| 9.
|
Chaussee, M. S.,
E. R. Phillips, and J. J. Feretti.
1997.
Temporal production of streptococcal erythrogenic toxin B (streptococcal cysteine proteinase) in response to nutrient depletion.
Infect. Immun.
65:1956-1959[Abstract].
|
| 10.
|
Cleary, P. P.,
E. L. Kaplan,
J. P. Handley, et al.
1992.
Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s.
Lancet
339:518-521[Medline].
|
| 11.
|
Cleary, P. P.,
L. McLandsborough,
L. Ikeda,
D. Cue,
J. Krawczak, and H. Lam.
1998.
High-frequency intracellular infection and erythrogenic toxin A expression undergo phase variation in M1 group A streptococci.
Mol. Microbiol.
28:157-167[Medline].
|
| 12.
|
Gerlach, D.,
H. Knöll,
W. Köhler,
J. H. Ozegowski, and V. Hribalova.
1983.
Isolation and characterization of erythrogenic toxins. V. Identity of erythrogenic toxin type B and streptococcal proteinase precursor.
Zentol. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. 1 Orig.
255:221-233.
|
| 13.
|
Hauser, A. R., and P. M. Schlievert.
1990.
Nucleotide sequence of the streptococcal pyrogenic exotoxin type B gene and relationship between the toxin and the streptococcal proteinase precursor.
J. Bacteriol.
172:4536-4542[Abstract/Free Full Text].
|
| 14.
|
Hauser, A. R.,
D. L. Stevens,
E. L. Kaplan, and P. M. Schlievert.
1991.
Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes associated with toxic shock-like syndrome.
J. Clin. Microbiol.
29:1562-1567[Abstract/Free Full Text].
|
| 15.
|
Holm, S. E.,
A. Norrby,
A. Bergholm, and M. Norgren.
1992.
Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989.
J. Infect. Dis.
166:31-37[Medline].
|
| 16.
|
Houston, C. W., and J. J. Feretti.
1981.
Enzyme-linked immunosorbent assay for detection of type A streptococcal exotoxin: kinetics and regulation during growth of Streptococcus pyogenes.
Infect. Immun.
33:862-869[Abstract/Free Full Text].
|
| 17.
|
Kapur, V.,
S. Topouzis,
M. W. Majesky, et al.
1993.
A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin.
Microb. Pathog.
15:327-346[Medline].
|
| 18.
|
Kapur, V.,
M. W. Majewski,
L.-L. Li,
R. A. Black, and J. M. Musser.
1993.
Cleavage of interleukin 1 precursor to produce active IL-1 by a conserved extracellular cysteine protease from Streptococcus pyogenes.
Proc. Natl. Acad. Sci. USA
90:7676-7680[Abstract/Free Full Text].
|
| 19.
|
Kaufhold, A.,
A. Podbielski,
G. Baumgarten,
M. Blokpoel,
J. Top, and L. Schouls.
1994.
Rapid typing of group A streptococci by the use of DNA amplification and non-radioactive allele-specific oligonucleotide probes.
FEMS Microbiol. Lett.
119:19-26[Medline].
|
| 20.
|
Köhler, W.,
D. Gerlach, and H. Knöll.
1987.
Streptococcal outbreaks and erythrogenic toxin type A.
Zentbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. 1 Orig. Reihe A
266:104-115.
|
| 21.
| Lee, P. K., and P. M. Schlievert.
Quantification and toxicity of group A streptococcal pyrogenic
exotoxins in an animal model of toxic shock syndrome-like illness.
J. Clin. Microbiol. 27:1890-1892.
|
| 22.
|
Lukomski, S.,
S. Sreevatsan,
C. Amberg,
W. Reichardt,
M. Woischnik,
A. Podbielski, and J. M. Musser.
1997.
Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decrease mouse lethality of serotype M3 and M49 strains.
J. Clin. Invest.
99:2574-2580[Medline].
|
| 23.
|
Lukomski, S.,
E. H. Burns,
P. R. Wyde,
A. Podbielski,
J. Rurangirwa,
D. K. Moore-Poveda, and J. M. Musser.
1998.
Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs.
Infect. Immun.
66:771-776[Abstract/Free Full Text].
|
| 24.
|
Marrack, P., and J. Kappler.
1990.
The staphylococcal enterotoxins and their relatives.
Science
248:705-711[Abstract/Free Full Text].
|
| 25.
|
Martin, D. R., and L. A. Single.
1993.
Molecular epidemiology of group A streptococcus M type 1 infections.
J. Infect. Dis.
167:1112-1117[Medline].
|
| 26.
|
Mascini, E. M.,
M. A. J. Hazenberg,
E. A. E. Verhage,
S. E. Holm,
J. Verhoef, and H. Van Dijk.
1996.
A new procedure for the purification of streptococcal pyrogenic exotoxin A from Streptococcus pyogenes supernatant.
Clin. Diagn. Lab. Immunol.
3:779-781[Abstract].
|
| 27.
|
Mollick, J. A.,
G. G. Miller,
J. M. Musser, et al.
1993.
A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with amino-terminal homology to staphylococcal enterotoxins B and C.
J. Clin. Invest.
92:710-719.
|
| 28.
|
Muotiala, A.,
H. Seppälä,
P. Huovinen, and J. Vuopio-Varkila.
1997.
Molecular comparison of group A streptococci of T1M1 serotype from invasive and noninvasive infections in Finland.
J. Infect. Dis.
175:392-399[Medline].
|
| 29.
|
Musser, J. M.,
A. R. Hauser,
M. H. Kim,
P. M. Schlievert,
K. Nelson, and R. K. Selander.
1991.
Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression.
Proc. Natl. Acad. Sci. USA
88:2668-2672[Abstract/Free Full Text].
|
| 30.
|
Musser, J. M.,
V. Kapur,
S. Kanjilal,
U. Shah,
D. M. Musher,
N. L. Barg,
K. H. Johnston,
P. M. Schlievert,
J. Henrichsen,
D. Gerlach,
R.M. Rakita,
A. Tanna,
B. D. Cookson, and J. C. Chang.
1993.
Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (scarlet fever toxin).
J. Infect. Dis.
167:337-346[Medline].
|
| 31.
|
Musser, J. M.,
V. Kapur,
J. Szeto,
X. Pan,
D. S. Swanson, and D. R. Martin.
1995.
Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease.
Infect. Immun.
63:994-1003[Abstract].
|
| 32.
|
Nelson, K.,
P. M. Schlievert,
R. K. Selander, and J. M. Musser.
1991.
Characterization and clonal distribution of four alleles of the spe-A gene encoding pyrogenic exotoxin A (scarlet fever toxin) in Streptococcus pyogenes.
J. Exp. Med.
174:1271-1274[Abstract/Free Full Text].
|
| 33.
|
Norgren, M.,
A. Norrby, and S. E. Holm.
1992.
Genetic diversity in T1M1 group A streptococci in relation to clinical outcome of infection.
J. Infect. Dis.
166:1014-1020[Medline].
|
| 34.
|
Norrby-Teglund, A.,
P. Pauksens,
S. E. Holm, and M. Norgren.
1994.
Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestations of disease.
J. Infect. Dis.
170:585-591[Medline].
|
| 35.
|
Norrby-Teglund, A.,
D. Newton,
M. Kotb,
S. E. Holm, and M. Norgren.
1994.
Superantigenic properties of the group A streptococcal exotoxin SpeF (MF).
Infect. Immun.
62:5227-5233[Abstract/Free Full Text].
|
| 36.
|
Ozegowski, J.-H.,
L. Wollweber,
S. Vettermann,
P.-J. Mueller,
E. Guenther, and W. Koehler.
1996.
Kinetics and regulation of erythrogenic toxins type A and C during growth of Streptococcus pyogenes.
Zentbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. 1 Orig.
283:271-285.
|
| 37.
|
Reichardt, W.,
H. Müller-Alouf,
J. E. Alouf, and W. Köhler.
1992.
Erythrogenic toxins A, B and C: occurrence of the genes and exotoxin formation from clinical Streptococcus pyogenes strains associated with streptococcal toxic shock-like syndrome.
FEMS Microbiol. Lett.
100:313-322.
|
| 38.
|
Roggiani, M., and P. M. Schlievert.
1994.
Streptococcal toxic shock syndrome, including necrotizing fasciitis and myositis.
Curr. Opin. Infect. Dis.
7:423-426.
|
| 39.
|
Roggiani, M.,
J. A. Stoehr,
B. A. B. Leonard, and P. M. Schlievert.
1997.
Analysis of toxicity of streptococcal pyrogenic exotoxin A mutants.
Infect. Immun.
65:2868-2875[Abstract].
|
| 40.
|
Schellekens, J. F. P.,
L. Schouls,
A. van Silfhout,
K. Elzenaar,
H. Brunings,
H. ten Broek,
J. Top, and W. J. van Leeuwen.
1995.
The resurgence of group A streptococcal disease: characteristics of invasive infections in the Netherlands, 1993-1995.
Ned. Tijdschr. Med. Microbiol.
3:78-83.
|
| 41.
|
Schellekens, J. F. P.,
L. Schouls,
W. van Pelt,
M. Esveld, and W. J. van Leeuwen.
1998.
Group A streptococci: a change in virulence?
Netherlands J. Med.
52:209-217[Medline].
|
| 42.
|
Schouls, L. M.,
M. C. J. Blokpoel,
K. P. Elzenaar,
J. F. P. Schellekens,
J. D. A. van Embden, and W. J. van Leeuwen.
1992.
Genotyping of M- and exotoxin genes in the surveillance of group A streptococci infections in The Netherlands.
RIVM Ann. Sci. Rep.
119:155-158.
|
| 43.
|
Stanley, J.,
D. Linton,
M. Desai,
A. Efstratiou, and R. George.
1995.
Molecular subtyping of prevalent M serotypes of Streptococcus pyogenes causing invasive disease.
J. Clin. Microbiol.
33:2850-2855[Abstract].
|
| 44.
|
Stevens, D. L.,
M. H. Tanner,
J. Winship,
R. Swarts,
K. M. Ries,
P. M. Schlievert, and E. L. Kaplan.
1989.
Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A.
N. Engl. J. Med.
321:1-7[Abstract].
|
| 45.
|
Talkington, D. F.,
B. Schwartz,
C. M. Black,
J. K. Todd,
J. Elliott,
R. F. Breimann, and R. R. Facklam.
1993.
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome.
Infect. Immun.
61:3369-3374[Abstract/Free Full Text].
|
| 46.
|
Tyler, S. D.,
W. M. Johnson,
J. C. Huang,
F. E. Ashton,
G. Wang,
D. E. Low, and K. R. Rozee.
1992.
Streptococcal erythrogenic toxin genes: detection by polymerase chain reaction and association with disease in strains isolated in Canada from 1940 to 1991.
J. Clin. Microbiol.
30:3127-3131[Abstract/Free Full Text].
|
| 47.
|
Upton, M.,
P. E. Carter,
G. Orange, and G. H. Pennington.
1996.
Genetic heterogeneity of M type 3 group A streptococci causing severe infections in Tayside, Scotland.
J. Clin. Microbiol.
34:196-198[Abstract].
|
| 48.
|
Weeks, C. A., and J. J. Feretti.
1986.
Nucleotide sequence of the type A streptococcal exotoxin (erythrogenic toxin) gene from Streptococcus pyogenes bacteriophage T12.
Infect. Immun.
52:144-150[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, November 1999, p. 3469-3474, Vol. 37, No. 11
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.